Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report

Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report

BackgroundMicrosatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) represents a distinct molecular phenotype observed in malignant tumors. These tumors typically exhibit high levels of programmed cell death 1 ligand 1 (PD-L1) expression and high tumor mutational burden (TMB), resu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiang Liu, Xiumei Zhang, Qun Ren, Chuanjun Song, Jianhe Yu, Yin Cai, Dadong Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Oncology
Subjects:	microsatellite instability high mismatch repair-deficient gastric cancer immunotherapy case report
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1484802/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
by: Yupeng Jiang, et al.
Published: (2025-02-01)

Updates on DNA Repair Gene Deficiency in Colorectal Cancer (dMMR)
by: Gustavo Sevá-Pereira, et al.
Published: (2025-03-01)

Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure
by: Qianwen Huang, et al.
Published: (2025-04-01)

Immunotherapy strategies and pharmaceutical care practice on a long-term surviving patient with advanced gastric cancer and mismatch repair deficient
by: Jinyin LI, et al.
Published: (2025-08-01)

Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studyResearch in context
by: Liying Zhao, et al.
Published: (2025-09-01)

Is neoadjuvant immunotherapy feasible for patients with dMMR/MSI−H locally advanced colorectal cancer? a retrospective study
by: Zhenkai Luo, et al.
Published: (2025-08-01)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024-01-01)

Microsatellite instability in stage II and III colorectal cancer: Patterns and profile
by: A P Dubey, et al.
Published: (2018-01-01)

Clinicopathological features of colon cancer depending on the dMMR status of the tumor
by: S. S. Naumov, et al.
Published: (2024-01-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

Early-stage endometrioid carcinoma with MSH6 protein deficiency: pitfalls in the diagnostic interpretation of microsatellite instability
by: Cheng Wang, et al.
Published: (2025-05-01)

Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
by: A. S. Tyulyandina, et al.
Published: (2023-05-01)

Association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors
by: Claire E. Thomas, et al.
Published: (2024-12-01)

Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor
by: Koushiro Ohtsubo, et al.
Published: (2025-03-01)

Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma
by: Zachary Kaplan, et al.
Published: (2025-05-01)

Salvage treatment of a metastatic colorectal cancer with pMMR/MSS in a 21-year-old man: a case report
by: Xuesong Li, et al.
Published: (2025-08-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

DMMR status and synchronous lesions predicts metachronous lesions after curative resection for rectal cancer
by: Xijie Chen, et al.
Published: (2025-01-01)

MSI expresso: a software for determining MSI status and detecting MSI-related transcription events from RNA sequencing data
by: Emmanuel Tubacher, et al.
Published: (2025-04-01)

A Prospective Study to Evaluate the Prevalence of Microsatellite Instability in Endometrial Carcinoma by using Immunohistochemistry for Mismatch Repair Proteins as a Surrogate Marker
by: Prithviraj K. Solanki, et al.

Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer
by: Ziyang Zeng, et al.
Published: (2025-05-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

[Comment] Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
by: Zhang Nan
Published: (2024-04-01)

Case Report: Lasting complete response to pembrolizumab in mismatch repair-deficient cardiac sarcoma: a genomic characterization
by: Daniela A. Ferraro, et al.
Published: (2025-04-01)

Microsatellite instability (MSI, EMAST) in the pathogenesis of follicular lymphoma
by: K. A. Sychevskaya, et al.
Published: (2021-06-01)

Does sex of the patient play a role in survival for MSI colorectal cancer?
by: Adrian Tulin, et al.
Published: (2018-04-01)

Research progress of immune checkpoint inhibitors in neoadjuvant immunotherapy for dMMR/MSI-H locally advanced colorectal cancer
by: Zhu Xi, et al.
Published: (2024-02-01)

Intratumoral and peritumoral radiomics for forecasting microsatellite status in gastric cancer: a multicenter study
by: Yunzhou Xiao, et al.
Published: (2025-01-01)

Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report
by: Alessia Lancianese, et al.
Published: (2025-06-01)

PHENOTYPIC FEATURES OF ENDOMETRIAL CANCER AND MSI IN COLON AND BLOOD SERUM
by: S. M. Kartashov, et al.
Published: (2014-04-01)

This is not Lynch syndrome: lessons from misattributed diagnoses in constitutional mismatch repair deficiency
by: A.H. Mohammad, et al.
Published: (2024-12-01)

Immunotherapy With Pembrolizumab for Resectable dMMR/MSI-H Stage III Colon Cancer: A Case of Personalized, Precision Surgery-Sparing Immunotherapy
by: Stanley Kim MD, et al.
Published: (2025-08-01)

Germline variants of the MMR/EPCAM genes in Russian patients with Lynch syndrome
by: Aleksey S. Tsukanov, et al.
Published: (2024-09-01)

More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients
by: Kaname Miyashita, et al.
Published: (2024-11-01)

Targeting MMR-deficient colorectal cancer with a potent small molecule UNI110
by: Enkhzul Amarsanaa, et al.
Published: (2025-12-01)

Human Epidermal Growth Factor Receptor 2 [HER‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
by: Samaneh Salarvand, et al.
Published: (2025-08-01)

Molecular features of malignant gastric tumors
by: Yu. A. Gevorkyan, et al.
Published: (2023-03-01)

Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study
by: Qiong Yang, et al.
Published: (2025-07-01)

Gamma Knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis
by: Yiran Zhang, et al.
Published: (2025-06-01)

Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma
by: Jiaqi Chen, et al.
Published: (2025-06-01)